Tags

Type your tag names separated by a space and hit enter

Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19.
Biochim Biophys Acta Mol Basis Dis. 2021 02 01; 1867(2):166014.BB

Abstract

The coronavirus disease 2019 (COVID-19) has been threatening the globe since the end of November 2019. The disease revealed cracks in the health care system as health care providers across the world were left without guidelines on definitive usage of pharmaceutical agents or vaccines. The World Health Organization (WHO) declared COVID-19 as a pandemic on the 11th of March 2020. Individuals with underlying systemic disorders have reported complications, such as cytokine storms, when infected with the virus. As the number of positive cases and the death toll across the globe continue to rise, various researchers have turned to cell based therapy using stem cells to combat COVID-19. The field of stem cells and regenerative medicine has provided a paradigm shift in treating a disease with minimally invasive techniques that provides maximal clinical and functional outcome for patients. With the available evidence of immunomodulatory and immune-privilege actions, mesenchymal stem cells (MSCs) can repair, regenerate and remodulate the native homeostasis of pulmonary parenchyma with improved pulmonary compliance. This article revolves around the usage of novel MSCs therapy for combating COVID-19.

Authors+Show Affiliations

Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street/MS/9410/4B 207, Lubbock, TX 79430, United States of America.Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street/MS/9410/4B 207, Lubbock, TX 79430, United States of America.Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India.Department of Plastic Surgery, Topiwala National Medical College and BYL Nair Ch. Hospital, Mumbai, Maharashtra, India.School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India.Department of Biotechnology, School of Life Science, Mahatma Gandhi Central University, Motihari, Bihar, India.Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.Department of Life Science, School of Basic Science and Research, Sharda University, Greater Noida, Uttar Pradesh, India.Department of Applied Physics, School of Science, Aalto University, Espoo, Finland.Department of Biotechnology, School of Life Science, Mahatma Gandhi Central University, Motihari, Bihar, India.Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India. Electronic address: saurabh.jha@sharda.ac.in.Internal Medicine, Neuroscience/Pharmacology, Neurology, Public Health Departments and School of Health Professions, Texas Tech University Health Sciences Center, 3601 4th Street/MS/9410/4B 207, Lubbock, TX 79430, United States of America. Electronic address: hemachandra.reddy@ttuhsc.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

33232817

Citation

Jeyaraman, Madhan, et al. "Fostering Mesenchymal Stem Cell Therapy to Halt Cytokine Storm in COVID-19." Biochimica Et Biophysica Acta. Molecular Basis of Disease, vol. 1867, no. 2, 2021, p. 166014.
Jeyaraman M, John A, Koshy S, et al. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochim Biophys Acta Mol Basis Dis. 2021;1867(2):166014.
Jeyaraman, M., John, A., Koshy, S., Ranjan, R., Anudeep, T. C., Jain, R., Swati, K., Jha, N. K., Sharma, A., Kesari, K. K., Prakash, A., Nand, P., Jha, S. K., & Reddy, P. H. (2021). Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochimica Et Biophysica Acta. Molecular Basis of Disease, 1867(2), 166014. https://doi.org/10.1016/j.bbadis.2020.166014
Jeyaraman M, et al. Fostering Mesenchymal Stem Cell Therapy to Halt Cytokine Storm in COVID-19. Biochim Biophys Acta Mol Basis Dis. 2021 02 1;1867(2):166014. PubMed PMID: 33232817.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. AU - Jeyaraman,Madhan, AU - John,Albin, AU - Koshy,Santhosh, AU - Ranjan,Rajni, AU - Anudeep,Talagavadi Channaiah, AU - Jain,Rashmi, AU - Swati,Kumari, AU - Jha,Niraj Kumar, AU - Sharma,Ankur, AU - Kesari,Kavindra Kumar, AU - Prakash,Anand, AU - Nand,Parma, AU - Jha,Saurabh Kumar, AU - Reddy,P Hemachandra, Y1 - 2020/11/22/ PY - 2020/08/07/received PY - 2020/11/05/revised PY - 2020/11/06/accepted PY - 2020/11/25/pubmed PY - 2021/1/12/medline PY - 2020/11/24/entrez KW - COVID-19 KW - Coronavirus KW - Mesenchymal stem cells KW - WHO SP - 166014 EP - 166014 JF - Biochimica et biophysica acta. Molecular basis of disease JO - Biochim Biophys Acta Mol Basis Dis VL - 1867 IS - 2 N2 - The coronavirus disease 2019 (COVID-19) has been threatening the globe since the end of November 2019. The disease revealed cracks in the health care system as health care providers across the world were left without guidelines on definitive usage of pharmaceutical agents or vaccines. The World Health Organization (WHO) declared COVID-19 as a pandemic on the 11th of March 2020. Individuals with underlying systemic disorders have reported complications, such as cytokine storms, when infected with the virus. As the number of positive cases and the death toll across the globe continue to rise, various researchers have turned to cell based therapy using stem cells to combat COVID-19. The field of stem cells and regenerative medicine has provided a paradigm shift in treating a disease with minimally invasive techniques that provides maximal clinical and functional outcome for patients. With the available evidence of immunomodulatory and immune-privilege actions, mesenchymal stem cells (MSCs) can repair, regenerate and remodulate the native homeostasis of pulmonary parenchyma with improved pulmonary compliance. This article revolves around the usage of novel MSCs therapy for combating COVID-19. SN - 1879-260X UR - https://www.unboundmedicine.com/medline/citation/33232817/Fostering_mesenchymal_stem_cell_therapy_to_halt_cytokine_storm_in_COVID_19_ DB - PRIME DP - Unbound Medicine ER -